AzTrials
AzTrials

Healthy VolunteersPhase 1NCT02923791

A Study in Healthy Volunteers to Assess Immune Response to Multiple Injections of Filgrastim Hospira or Neupogen Reference Product.

A Phase 1 study testing Filgrastim Hospira and US-Approved Neupogen in people with Healthy Volunteers, run by Pfizer at 3 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study compares the potential immunogenicity of two filgrastims, the proposed biosimilar Filgrastim Hospira (US) and the US-approved Neupogen reference product. Subjects will receive doses of one of the two filgrastims by injection of 5 micrograms/kilogram (mcg/kg). Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Healthy Volunteers
What is being tested?
Filgrastim Hospira and US-Approved Neupogen
Could I receive a placebo?
No, everyone receives an active treatment
How many people
256 participants
Where
3 sitesUnited States
Study dates
Oct 2016to Jan 2017
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Healthy male or female volunteers between 18 and 65 years of age (both inclusive).
  • Body mass index (BMI) between 19 and 30 kg/m2, inclusive, and body weight of not < 50 kg or >95 kg.
  • Subjects have abstained from the use of tobacco- or nicotine-containing products for at least 90 days prior to dosing and have a negative urine screen for cotinine at Screening.
  • Agrees to abstain from alcohol consumption for at least 48 hours prior to Day 1 of dosing in each study period and throughout the 5 days of study treatment and has a negative urine screen for alcohol at Screening.
Show all 10Show fewer
  • Female subjects of non-childbearing potential must meet at least 1 of the following criteria:
  • Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status will be confirmed by having a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state;
  • Have undergone a documented hysterectomy and/or bilateral oophorectomy;
  • Have medically confirmed ovarian failure. All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential

Who cannot join

  • Subjects with any of the following characteristics/conditions will not be included in the study:
  • Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  • Participation in other studies involving an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of investigational product (whichever is longer) prior to study entry and/or during study participation.
  • Acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  • Any active systemic or immunologic disease or condition, including but not limited to the following general categories: cardiovascular/pulmonary, hepatorenal, or systemic infection, or lactation.
  • History of malignancy or current malignancy with the exception of adequately treated squamous or basal cell carcinoma of the skin or cervical carcinoma in situ within 5 years.
Show all 23Show fewer
  • Any disease or condition that might interfere with the absorption, distribution, metabolism, or excretion of the study drug or would place the subject at increased risk.
  • Hematologic laboratory abnormalities including leukocytosis (defined as total leukocytes >11,000/mcL), leukopenia (defined as total leukocytes <4000/mcL), or neutropenia (defined as absolute neutrophil count [ANC] <1500/mcL), or thrombocytopenia (defined as platelet count of <150/mcL).
  • Lacks adequate hepatic reserve as defined by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 1.5 x the upper limit of normal (ULN) of the reference lab; lack of renal reserve as defined by serum creatinine of ≥1.2 x ULN for reference lab or estimated glomerular filtration rate (eGFR) of ≤ 80 mg/min; or has known history of glomerulonephritis.
  • Clinically significant, as judged by the investigator, vital sign, or 12-lead electrocardiogram (ECG) abnormality.
  • History of biological growth factor exposure, including but not limited to filgrastim and other G-CSFs in the context of treatment, prophylaxis, peripheral blood stem cell mobilization, or previous investigational study setting.
  • Receipt of live vaccination, or exposure to communicable viral diseases such as chicken pox, varicella, or measles within the 4 weeks prior to Screening.
  • Surgery within the 4 months prior to Screening.
  • Use of any prescription medicine (with the exception of contraceptives) within 7 days or at least 5 half-lives, whichever is longer. Use of oral or parenteral anticoagulant or antiplatelet agents and corticosteroids should be specifically queried.
  • Administration of a drug by depot injection (with exception of depot contraception) within 30 days prior to the initial study drug administration or 5 half-lives of that drug, whichever is longer.
  • Use of over the counter medications, including aspirin and non-steroidal anti-inflammatory drugs, or natural preparations (dietary supplement or herbal product) within 7 days or at least 5 half-lives, whichever is longer. Vitamins and calcium supplements are allowed (not to exceed 100% daily value).
  • History of drug or alcohol abuse within 2 years prior to randomization, as determined by the investigator or a positive urine screen for drugs of abuse at Screening. Screening for drugs of abuse will minimally include cannabinoids, opiates, barbiturates, amphetamines, cocaine, and benzodiazepines.
  • Drug sensitivity, allergic reaction to, or known hypersensitivity/idiosyncratic reaction to E. coli-derived proteins, filgrastim, pegfilgrastim, other G-CSFs or any component of the product: subjects with the rare heredity problem of fructose intolerance are excluded due to the excipient sorbitol.
  • History of splenic rupture (or subject who is asplenic), pulmonary infiltrate or pneumonia, sickle cell disorders, chronic neutropenia, thrombocytopenia, or vasculitis.
  • Any clinically significant, as determined by the investigator, abnormal laboratory evaluations, including human immunodeficiency virus antibody (HIVAb), hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (HCVAb) and liver function taken at Screening. Negative HIVAb status will be confirmed at Screening and the results will be maintained confidentially by the study site.
  • Blood donation (including plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing OR had a transfusion of any blood product within 90 days prior to Screening.
  • Pregnant female subjects, breastfeeding female subjects, fertile male subjects and female subjects of childbearing potential who are unwilling or unable to use at least 1 highly effective method of contraception as outlined in the protocol for the duration of the study and for at least 28 days after the last dose of investigational product.
  • Unwilling or unable to comply with the criteria in the Lifestyle Requirements section of the protocol.

Trial locations and contacts

3 sites in 1 country.

United States3 sites

  • SeaView Research, Inc.

    Coral Gables, Florida, 33134

  • Seaview Jacksonville LLC

    Jacksonville, Florida, 32256

  • SeaView Research, Inc.

    Miami, Florida, 33126

Other trials in United States

About this study

Official title: A Phase I, Randomized Open-label, 2-period, Parallel Arm Study To Assess The Immunogenicity Of Multiple Subcutaneous (SC) Doses Of "Filgrastim Hospira" (US) Or US-approved Neupogen(Registered) Reference Product In Healthy Volunteers

This study compares the potential immunogenicity of two filgrastims, the proposed biosimilar Filgrastim Hospira (US) and the US-approved Neupogen reference product. Subjects will receive doses of one of the two filgrastims by injection of 5 micrograms/kilogram (mcg/kg). Subjects will receive 5 consecutive daily doses in Period 1 (Days 1-5) and a single dose on Day 1 of Period 2. Pre-dose and serial post-dose assessments of immunogenicity will be conducted each of the two study periods. In addition, safety assessments will be conducted throughout the study.

Being tested
Filgrastim Hospira, US-Approved Neupogen

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Filgrastim HospiraBiological

    Also called Filgrastim

    5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.

  • US-Approved NeupogenBiological

    Also called Filgrastim

    5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.

Study groups in NCT02923791
Study groupRoleWhat they receive
Filgrastim HospiraExperimentalNot described
Receives: Biological: Filgrastim Hospira
US-Approved NeupogenActive comparatorNot described
Receives: Biological: US-Approved Neupogen

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The proportion of subjects with a negative baseline anti-drug antibody (ADA) test result and confirmed post-dose positive ADA test result at any time during the study.

    Measured: 62 days (Period 1 Day 0 through Period 2 Day 31 or Final Visit)

Secondary outcomes (1)

  1. The proportion of subjects with a negative baseline ADA test result and post-dose positive neutralizing antibody result at any time during the study;

    Measured: 62 days (Period 1 Day 0 through Period 2 Day 31 or Final Visit)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Oct 2016 (estimated)
  2. Study startOct 2016
  3. Primary completionJan 2017
  4. Study completionJan 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
256 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02923791
Sponsor's protocol ID
C1121012
Other IDs
FILGRASTIM IMMUNOGENICITY US, COMPARATIVE IMMUNOGENICITY
Status last verified
Feb 2017
First submitted
30 Sep 2016
Last updated
23 Feb 2017
Results posted
No
Data monitoring committee
No

Publications

  • Yao HM, Ottery FD, Borema T, Harris S, Levy J, May TB, Moosavi S, Zhang J, Summers M. PF-06881893 (Nivestym), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen(R)): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers. BioDrugs. 2019 Apr;33(2):207-220. doi: 10.1007/s40259-019-00343-8.

    PubMed 30900158

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Filgrastim Hospira and US-Approved Neupogen in people with Healthy Volunteers, run by Pfizer at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The proportion of subjects with a negative baseline anti-drug antibody (ADA) test result and confirmed post-dose positive ADA test result at any time during the study. (time frame: 62 days (Period 1 Day 0 through Period 2 Day 31 or Final Visit)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02923791, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2017.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in